An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Ovarian Carcinoma
- Sponsor
- City of Hope Medical Center
- Locations
- 1
- Primary Endpoint
- Adherence to the data collection and exercise trial protocol, defined as the number of sessions attended, questionnaires completed, and blood samples completed
- Status
- Withdrawn
- Last Updated
- 7 years ago
Overview
Brief Summary
This clinical trial studies how well an exercise intervention works in reducing symptoms and improving clinical outcomes in patients with ovarian cancer undergoing platinum-based chemotherapy. Exercise may "train" the body to repair deoxyribonucleic acid (DNA) damage more efficiently, which may reduce symptoms related to platinum-based chemotherapy, improve quality of life, increase survival, and decrease recurrence rates in patients with ovarian cancer.
Detailed Description
PRIMARY OBJECTIVES: I. To assess the feasibility of recruiting and enrolling newly diagnosed epithelial ovarian cancer patients who have undergone debulking surgery and will be starting platinum-based chemotherapy, to an exercise trial. II. To evaluate adherence to the data collection and exercise trial protocol. It is necessary to determine the feasibility of collecting tablet-based questionnaire data and blood samples at multiple time points in one visit. It is also critical to determine whether the exercise intervention is feasible in this patient population. SECONDARY OBJECTIVES: I. To examine changes in DNA repair function before and after a single exercise session. II. To examine changes in DNA repair function, body composition, quality of life, symptoms and patient satisfaction with care over the treatment time course. III. To examine the effect of the exercise intervention on these measurements. IV. To follow the patients an additional 12-months for clinical outcomes defined as death, cancer recurrence, or new primary cancer. OUTLINE: Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum. After completion of study, patients are followed up for 12 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women who have been newly diagnosed with a first primary, epithelial ovarian cancer, have undergone surgical debulking and who will be treatment according to the Armstrong method
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.
- •Newly diagnosed, primary, epithelial ovarian cancer
- •Have undergone surgical debulking
- •Will be treated according to the Armstrong method
- •Read and understand English
- •All subjects must have the ability to understand and the willingness to sign a written informed consent
Exclusion Criteria
- •Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Outcomes
Primary Outcomes
Adherence to the data collection and exercise trial protocol, defined as the number of sessions attended, questionnaires completed, and blood samples completed
Time Frame: 18 weeks
Feasibility of recruiting and enrolling patients to an exercise trial, defined as the number of people contacted, eligible consented and enrolled
Time Frame: 12 months
Secondary Outcomes
- Change in body composition(Baseline to 18 weeks)
- Change in DNA repair function, assessed by host reactivation assays(Baseline to 18 weeks)
- Change in quality of life, assessed by questionnaires(Baseline to 18 weeks)
- Change in symptoms, assessed by National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 version 2(Baseline to 18 weeks)
- Change in treatment satisfaction, assessed by Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General(Baseline to 18 weeks)
- Clinical outcome follow-up defined as death, cancer recurrence, or new primary cancer(Up to 12 months)